US4789541A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and composition for in vivo radiolabeling of red blood cells with 99m Tc
Assignee: Nuclear Diagnostics Inc
•
Filing: 1987-06-16
•
Granted: 1988-12-06
•
Expires: 2007-06-16
Abstract
Abstract A composition containing stannous chloride and potassium perchlorate is suitable for oral administration to a patient for tinning red blood cells of the patient in vivo prior to labeling the red blood cells with radioactive 99m Tc. The composition is useful for preparing a patient for blood pool imaging, and especially for carrying out equilibrium gated cardiac imaging.
Inventors
- 👤 Michael H. Davis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:42
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1203; A61K2123/00
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
68 words
A pill in the form of a tablet or capsule suitable for oral administration to a patient for tinning red blood cells of the patient in vivo in preparation for radiolabeling the red blood cells with 99m Tc, wherein said pill comprises a composition consisting essentially of (1) about 10 mg to about 200 mg stannous chloride, and (2) about 250 mg to about 1000 mg potassium perchlorate.
Claim 2
Dependent Claim
68 words
A pill in the form of a tablet or capsule suitable for oral administration to a patient for tinning red blood cells of the patient in vivo in preparation for radiolabeling the red blood cells with 99m Tc, wherein said pill comprises a composition consisting essentially of (1) about 10 mg to about 200 mg stannous chloride, and (2) about 250 mg to about 1000 mg potassium perchlorate.
Claim 3
Dependent Claim
15 words
A pill according to claim 1, in which the stannous chloride is stannous chloride dihydrate.
Claim 4
Dependent Claim
14 words
A pill according to claim 1, wherein said composition contains a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
25 words
A pill according to claim 1, in which the stannous chloride and potassium perchlorate are in a weight ratio of about 1:5 to about 1:100.
Claim 6
Dependent Claim
25 words
A pill according to claim 1, in which the stannous chloride and potassium perchlorate are in a weight ratio of about 1:20 to about 1:30.
Claim 7
Dependent Claim
22 words
A pill according to claim 1, in which the stannous chloride and potassium perchlorate are in a weight ratio of about 1:24.
Claim 8
Dependent Claim
14 words
A pill according to claim 5, wherein said composition contains a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
27 words
A pill according to claim 7, wherein said composition consists essentially of 25 mg SnCl 2 .2H 2 O(±1 mg) and about 600 mg KClO 4 .
Claim 10
Independent Claim
82 words
A method of treating a mammalian patient for tinning red blood cells in vivo, said method comprising orally administering to the patient about 8.9 mg/kg body weight to about 10 mg/kg body weight of a composition consisting essentially of (1) about 10 mg to about 200 mg stannous chloride, and (2) about 250 mg to about 1000 mg potassium perchlorate; and incubating red blood cells in vivo for a time sufficient for Sn 2+ to be absorbed by the red blood cells.
Claim 11
Independent Claim
82 words
A method of treating a mammalian patient for tinning red blood cells in vivo, said method comprising orally administering to the patient about 8.9 mg/kg body weight to about 10 mg/kg body weight of a composition consisting essentially of (1) about 10 mg to about 200 mg stannous chloride, and (2) about 250 mg to about 1000 mg potassium perchlorate; and incubating red blood cells in vivo for a time sufficient for Sn 2+ to be absorbed by the red blood cells.
Claim 12
Dependent Claim
23 words
Method according to claim 9, wherein the stannous chloride and potassium perchlorate are in a weight ratio of about 1:5 to about 1:100.
Claim 13
Dependent Claim
23 words
Method according to claim 9, wherein the stannous chloride and potassium perchlorate are in a weight ratio of about 1:20 to about 1:30.
Claim 14
Dependent Claim
20 words
Method according to claim 9, wherein the stannous chloride and potassium perchlorate are in a weight ratio of about 1:24.
Claim 15
Dependent Claim
25 words
Method according to claim 9, wherein the red blood cells are incubated in vivo with Sn 2+ for about 10 minutes to about 120 minutes.
Claim 16
Dependent Claim
11 words
Method according to claim 9, wherein the patient is a human.
Claim 17
Dependent Claim
13 words
Method according to claim 9, wherein the mammal is a canine or feline.
Claim 18
Independent Claim
114 words
A method for radiolabeling red blood cells of a patient, said method comprising orally administering to the patient about 8.9 mg/kg body weight to about 42 mg/kg body weight of a composition consisting essentially of (1) about 10 mg to about 200 mg stannous chloride, and (2) about 250 mg to about 1000 mg potassium perchlorate; incubating red blood cells in vivo in the presence of Sn 2+ for a time sufficient for tin to be absorbed by the red blood cells in the patient; contacting the resulting tinned red blood cells with 99m Tc; and incubating the tinned red blood cells with the 99m Tc for a time sufficient to radiolabel the cells.
Claim 19
Independent Claim
114 words
A method for radiolabeling red blood cells of a patient, said method comprising orally administering to the patient about 8.9 mg/kg body weight to about 42 mg/kg body weight of a composition consisting essentially of (1) about 10 mg to about 200 mg stannous chloride, and (2) about 250 mg to about 1000 mg potassium perchlorate; incubating red blood cells in vivo in the presence of Sn 2+ for a time sufficient for tin to be absorbed by the red blood cells in the patient; contacting the resulting tinned red blood cells with 99m Tc; and incubating the tinned red blood cells with the 99m Tc for a time sufficient to radiolabel the cells.
Claim 20
Dependent Claim
15 words
Method according to claim 16, wherein the 99m Tc is intravenously administered to the patient.
Claim 21
Dependent Claim
14 words
Method according to claim 17, wherein the 99m Tc is derived from sodium pertechnetate.
Claim 22
Dependent Claim
27 words
Method according to claim 18, wherein the 99m Tc is administered in an amount of about 0.2 mCi/kg to about 0.43 mCi/kg of the patient's body weight.
Claim 23
Dependent Claim
24 words
Method according to claim 19, wherein labeling yield of red blood cells is at least about 90% at 45 minutes after 99m Tc dosing.
Claim 24
Independent Claim
135 words
A method of carrying out equilibrium blood pool imaging in a patient, said method comprising orally administering to the patient about 8.9 mg/kg body weight to about 42 mg/kg body weight of a composition consisting essentially of (1) about 10 to about 200 mg stannous chloride, and (2) about 250 mg to about 1000 mg potassium perchlorate; incubating red blood cells in vivo in the presence of Sn 2+ for a time sufficient for tin to be absorbed by the red blood cells in the patient; contacting the resulting tinned red blood cells with 99m Tc; and incubating the tinned red blood cells with the 99m Tc for a time sufficient to radiolabel the cells; and imaging a blood pool of the patient with means for detecting and reporting radioactivity emitted by the 99m Tc.
Claim 25
Independent Claim
135 words
A method of carrying out equilibrium blood pool imaging in a patient, said method comprising orally administering to the patient about 8.9 mg/kg body weight to about 42 mg/kg body weight of a composition consisting essentially of (1) about 10 to about 200 mg stannous chloride, and (2) about 250 mg to about 1000 mg potassium perchlorate; incubating red blood cells in vivo in the presence of Sn 2+ for a time sufficient for tin to be absorbed by the red blood cells in the patient; contacting the resulting tinned red blood cells with 99m Tc; and incubating the tinned red blood cells with the 99m Tc for a time sufficient to radiolabel the cells; and imaging a blood pool of the patient with means for detecting and reporting radioactivity emitted by the 99m Tc.
Claim 26
Dependent Claim
129 words
A kit for tinning red blood cells of a patient in vivo in preparation for radiolabeling the cells with 99m Tc, wherein the kit contains a drug consisting essentially of (1) a solid, unit dose of stannous compound consisting essentially of about 10 mg to about 200 mg of stannous chloride sufficient to tin the red blood cells in vivo; and (2) a solid, unit dose of potassium perchlorate in an amount of about 250 mg to about 1000 mg sufficient to substantially inhibit absorption of 99m Tc by the gut of a patient, while permitting the tinning of red blood cells and radiolabeling of red blood cells with 99m Tc; wherein the stannous chloride and potassium perchlorate are in a weight ratio of about 1:5 to about 1:100.
Claim 27
Dependent Claim
129 words
A kit for tinning red blood cells of a patient in vivo in preparation for radiolabeling the cells with 99m Tc, wherein the kit contains a drug consisting essentially of (1) a solid, unit dose of stannous compound consisting essentially of about 10 mg to about 200 mg of stannous chloride sufficient to tin the red blood cells in vivo; and (2) a solid, unit dose of potassium perchlorate in an amount of about 250 mg to about 1000 mg sufficient to substantially inhibit absorption of 99m Tc by the gut of a patient, while permitting the tinning of red blood cells and radiolabeling of red blood cells with 99m Tc; wherein the stannous chloride and potassium perchlorate are in a weight ratio of about 1:5 to about 1:100.
Claim 28
Dependent Claim
18 words
Kit according to claim 22, wherein each unit dose is in the form of a tablet or capsule.
Claim 29
Dependent Claim
19 words
Kit according to claim 23, wherein the tablets and capsules are individually sealed in separate compartments in a package.
Claim 30
Dependent Claim
25 words
Kit according to claim 24, wherein the dose of stannous chloride and the dose of potassium perchlorate are combined to form a single, solid dose.
Claim 31
Dependent Claim
19 words
Kit according to claim 25, wherein the kit includes directions for use of the drug contained in the kit.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-12-06 | 1992-06-06 | 1992-12-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-12-06 | 1996-06-06 | 1996-12-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-12-06 | 2000-06-06 | 2000-12-06 | $7700.00 | Window Closed / Lapsed |